These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 21295512

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
    Ren J, Stammers DK.
    Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
    [Abstract] [Full Text] [Related]

  • 7. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L, Azijn H, Rimsky LT, Vingerhoets J, Lecocq P, Kraus G, Picchio G, de Béthune MP.
    Antivir Ther; 2009 Jun; 14(1):103-9. PubMed ID: 19320243
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Essential benefits of nucleoside analogue regimens in failing therapy.
    Geretti AM.
    J HIV Ther; 2004 May; 9(2):28-33. PubMed ID: 15238873
    [Abstract] [Full Text] [Related]

  • 10. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
    de Béthune MP.
    Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
    [Abstract] [Full Text] [Related]

  • 11. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG.
    AIDS; 2009 Jul 31; 23(12):1605-8. PubMed ID: 19487903
    [Abstract] [Full Text] [Related]

  • 12. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
    Tucker TJ, Sisko JT, Tynebor RM, Williams TM, Felock PJ, Flynn JA, Lai MT, Liang Y, McGaughey G, Liu M, Miller M, Moyer G, Munshi V, Perlow-Poehnelt R, Prasad S, Reid JC, Sanchez R, Torrent M, Vacca JP, Wan BL, Yan Y.
    J Med Chem; 2008 Oct 23; 51(20):6503-11. PubMed ID: 18826204
    [Abstract] [Full Text] [Related]

  • 13. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
    Vaz P, Chaix ML, Jani I, Macassa E, Bila D, Vubil A, Anderson S, Rouzioux C, Briand N, Blanche S.
    Pediatr Infect Dis J; 2009 Dec 23; 28(12):e283-7. PubMed ID: 19907359
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG.
    Antivir Ther; 2005 Dec 23; 10(2):357-61. PubMed ID: 15865231
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L.
    Virus Res; 2008 Jun 23; 134(1-2):124-46. PubMed ID: 18272247
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, Calvez V.
    J Med Virol; 2004 Jan 23; 72(1):162-5. PubMed ID: 14635026
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.